Gain Therapeutics, Inc. Common Stock (GANX) is a publicly traded Healthcare sector company. As of May 21, 2026, GANX trades at $1.67 with a market cap of $69.10M and a P/E ratio of -2.70. GANX moved +4.09% today. Year to date, GANX is -44.44%; over the trailing twelve months it is -13.61%. Its 52-week range spans $1.41 to $4.34. Analyst consensus is strong buy with an average price target of $7.20. Rallies surfaces GANX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
GANX financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. GANX recently traded at $1.67. Market cap is $69.10M. P/E ratio is -2.70. Revenue is $0.
| Metric | Value |
|---|---|
| Price | $1.67 |
| Market Cap | $69.10M |
| P/E Ratio | -2.70 |
| EPS | $-0.61 |
| Dividend Yield | 0.00% |
| 52-Week High | $4.34 |
| 52-Week Low | $1.41 |
| Volume | 17 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-20.16M |
| Gross Margin | 0.00% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0 | $-20.16M | $-0.61 |
| 2024 | $0 | $-20.41M | $-0.89 |
| 2023 | $55.18K | $-22.27M | $-1.71 |
| 2022 | $140.11K | $-17.59M | $-1.48 |
5 analysts cover GANX: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $7.20.